2019 ASCO Annual Meeting!
Session: Developmental Immunotherapy and Tumor Immunobiology
Type: Poster Session
Time: Saturday June 1, 8:00 AM to 11:00 AM
Location: Hall A
Correlation of circulating EBV-targeted cytotoxic T lymphocyte precursors (EBV-CTLp) and clinical response following tabelecleucel (tab-cel) infusion in patients with EBV-driven disease.
Developmental Immunotherapy and Tumor Immunobiology
2019 ASCO Annual Meeting
Poster Board Number:
Poster Session (Board #176)
J Clin Oncol 37, 2019 (suppl; abstr 2532)
Author(s): Blake T. Aftab, Daniel Munson, Kevin Rasor, Philippe Foubert, Donald Edward Tsai, Wen-Kai Weng, Armin Ghobadi, Koen Van Besien, Yan Sun, Minoti Hiremath, Willis H. Navarro, Susan Prockop; Atara Biotherapeutics, Thousand Oaks, CA; Abramson Cancer Center, Philadelphia, PA; Stanford University Medical Center, Stanford, CA; Washington University in St. Louis, St. Louis, MO; Weill Cornell Medcl Coll, New York, NY; Atara Biotherapeutics, Inc., Thousand Oaks, CA; Atara Biotherapeutics, South San Francisco, CA; Memorial Sloan Kettering Cancer Center, New York, NY
Background: EBV is implicated in a variety of diseases. Tab-cel is an investigational off-the-shelf, allogeneic T-cell immunotherapy utilizing endogenous T cell receptors targeting EBV antigens. We hypothesized the clinical activity of tab-cel is mediated by expansion and persistence of EBV-specific T cells. Therefore, we quantified circulating EBV- CTLp after tab-cel administration and examined the correlation between expansion and clinical response. Methods: Samples from 10 patients with EBV+ post-transplant lymphoproliferative disease (PTLD) and other EBV-associated diseases enrolled in an multicenter expanded access protocol (EAP) study (